Enesi Pharma collaborates with Adelaide University for Zika vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Enesi Pharma collaborates with Adelaide University for Zika vaccine
Enesi Pharma's Implavax technology platform would try to make the vaccine needle free and thermally stable

Enesi Pharma, an innovative biotechnology company developing next-generation vaccination products targeting serious diseases, is delighted to announce its partnership with the University of Adelaide to develop a new thermostable, solid dose DNA vaccine for Zika virus to prevent infection of pregnant women and the resultant congenital effects in the unborn child.

This project aims to employ Enesi’s ImplaVax formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device. The innovative combination of this ImplaVax formulation and delivery system with the novel DNA vaccine construct developed by researchers at the University of Adelaide is expected to enhance the vaccine’s efficacy, thermal stability and allow for safe and rapid vaccination of target populations that are otherwise geographically and economically disadvantaged.

DNA and RNA vaccines are becoming increasingly prominent and hold great potential against many diseases, as highlighted by the ongoing Covid-19 crisis. However, they also present important thermostability challenges and require an uninterrupted end-to-end cold chain throughout to maintain potency up to the point of administration. Enesi’s ImplaVax technology aims to address these challenges by creating needle-free solid dose vaccines that are thermally stable at temperatures up to 40oC and eliminate the need for cold-chain storage and distribution.

The new AUD1.35 million collaboration with the University of Adelaide aims to advance the development of a novel thermostable, solid dose Zika virus DNA vaccine to Phase 1 clinical trials. The programme is being funded with AUD675,500 from the Australian Government’s Biomedical Translation Bridge (BTB) programme, and additional funding from Enesi Pharma, The Hospital Research Foundation, Adelaide Enterprise Commercial Accelerator Scheme and the University of Adelaide’s Faculty of Health and Medical Sciences.

David Hipkiss, Enesi Pharma CEO, commented:“We are delighted to enter this new partnership with the University of Adelaide, and to leverage our ImplaVax® technologies to tackle the significant public health issue that Zika virus infection represents. We are particularly excited that this new collaboration is focused on advancing the development of a solid dose DNA vaccine through application of our ImplaVax® technology. While holding huge promise, it is recognised that DNA and RNA vaccines have significant cold chain requirements, which could impact the efficiency and reach of final products.

“We believe that our ImplaVax technology could provide a solution to overcome these barriers. This belief is based upon our earlier work which has evidenced the ability for ImplaVax-enabled DNA vaccine candidates to be thermally stable and retain their immunogenicity potential. A positive outcome from our new collaboration, alongside other projects evaluating ImplaVax-enabled DNA and RNA vaccines, could help unlock the full potential of such approaches across a vast range of diseases, from Zika to Covid-19.”

Zika is a mosquito-transmitted ‘flavivirus’ currently circulating in the Americas and Asia, which causes microcephaly (a birth defect where a baby’s head is significantly smaller than expected) and other severe birth defects in infants born to infected mothers. These defects cannot be corrected, and the accompanying disabilities are lifelong and catastrophic. Zika can also cause Guillain-Barré syndrome in adults, and there is currently no therapy or approved vaccine available to prevent infection.

The Australian Government’s Biomedical Translation Bridge program, delivered by Australia’s Industry Growth Centre, MTPConnect, is an initiative of the Medical Research Future Fund, and aims to facilitate the translation of new therapies, technologies and medical devices through to the proof of concept stage.

Tags : #EnesiPharma #ImplavaxTechnology #ZikaVirusVaccine #Covid-19Vaccine #DNAbasedVaccine #RNAbasedVaccine #AdelaideUniversityZikaVirus

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026